Publications by authors named "M Pins"
Article Synopsis
- - Patients who had no evidence of disease (NED) after surgery for metastatic renal cell carcinoma (mRCC) were studied to see if pazopanib, a cancer medication, could improve their disease-free survival (DFS) compared to a placebo.
- - The trial included 129 patients, and after thorough analysis, it found no significant difference in 3-year DFS rates between the pazopanib group (27.4%) and placebo group (21.9%).
- - Additionally, the overall survival rate was better for the placebo group (91.4%) compared to pazopanib (81.9%), raising concerns about the drug's effectiveness and quality of life for patients on it.
Introduction: Sarcomatoid renal cancer (sRCC) patients have poor outcomes. EA1808 evaluated sunitinib and gemcitabine (SG) and sunitinib alone (S) in sRCC in a randomized cooperative group phase II trial (NCT01164228).
Patients And Methods: Pts were aggregated 1:1 to SG (45 pts) or S (40 pts) using a 2-stage design.
Objectives: To study the effects of adjuvant therapy in patients with sarcomatoid renal cell carcinoma (sRCC) enrolled in the randomised phase III clinical trial E2805.
Patients And Methods: The original trial (E2805) was a randomised, double-blinded phase III clinical trial comparing outcomes in 1943 patients with RCC accrued between 2006 and 2010 and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib. The present study analyses the cohort of patients with sRCC that participated in E2805.
Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Mod Pathol
September 2021
Article Synopsis
- This study looked at different types of tumors in the prostate that may come from special cells in the tissue.
- Researchers used advanced DNA and RNA testing on 25 tumors, finding many had genetic changes.
- The findings suggest these tumors are very different from each other and may not fit into one specific type, leading to questions about how they should be diagnosed.